Surbhi Sidana
A5017390274- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Monoclonal and Polyclonal Antibodies Research
- Neuroendocrine Tumor Research Advances
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Parathyroid Disorders and Treatments
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Renal Diseases and Glomerulopathies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Mechanisms and Therapy
- Cancer Genomics and Diagnostics
- Biomedical Ethics and Regulation
Stanford University
2019-2025
Palo Alto University
2022-2025
Stanford Blood Center
2023-2024
Stanford Medicine
2020-2024
Stanford Health Care
2023
Moffitt Cancer Center
2023
The University of Texas MD Anderson Cancer Center
2023
Bristol-Myers Squibb (Germany)
2023
Janssen (Belgium)
2023
Caribou Biosciences (United States)
2023
Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen myeloma cells. In phase 1 dose-defining portion study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.
Abstract Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten 16 large B cell lymphoma (LBCL) disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated To prevent relapse − lo disease, we tested a bispecific CAR targeting and/or CD22 (CD19-22.BB.z-CAR) in phase I clinical trial ( NCT03233854 ) adults relapsed/refractory acute...
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel earlier treatment lines lenalidomide-refractory disease. Download PDF of the Research Summary. In this phase 3, randomized, open-label trial, we assigned myeloma to receive physician's choice standard care. All had received one three previous treatment. The primary outcome was...
Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of phase II pivotal KarMMa trial, which demonstrated best overall and ≥ complete response rates 73% 33%, respectively. We report clinical outcomes with standard-of-care (SOC) ide-cel under commercial Food Drug Administration label.
Abstract Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We evaluated long-term course hematologic recovery, immune reconstitution, and infectious complications 41 patients with LBCL treated axicabtagene ciloleucel (axi-cel) at a single center. Grade 3+ cytopenias occurred 97.6% within first 28 days postinfusion, most resolved by 6 months. Overall, 63.4% received red...
Abstract Most patients with multiple myeloma experience disease relapse after treatment a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for treated sequential BCMA-TT are limited. We analyzed clinical infused standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 prior exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) 153 no were ide-cel, median follow-up...
8011 Background: Teclistamab is the first approved off-the-shelf BCMA×CD3 bispecific antibody for treatment of patients (pts) with RRMM based on data from pivotal phase 1/2 MajesTEC-1 study (NCT03145181/NCT04557098). Moreau et al ( NEJM 2022) reported rapid, deep, and durable responses: overall response rate (ORR) was 63% (39% ≥complete [CR] rate), a median duration (mDOR) 18.4 mo, progression-free survival (mPFS) 11.3 mo after follow-up (mFU) 14.1 mo. Here, we present updated results...
7540 Background: Teclistamab, the first approved B-cell maturation antigen × CD3 bispecific antibody (BsAb) with weight-based dosing for treatment of patients (pts) triple-class exposed relapsed/refractory multiple myeloma (RRMM), demonstrated rapid, deep, and durable responses in pivotal MajesTEC-1 study. Here, we report updated results from MajesTEC-1. Methods: Eligible pts received teclistamab at recommended phase 2 dose (RP2D; 1.5 mg/kg subcutaneous QW preceded by step-up dosing) option...
PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, survival among patients with RRMM treated standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of leukapheresed by December 31, 2022, the intent to receive SOC...
BackgroundMedical education is associated with various pressures and stresses which can lead to depression.This study was undertaken discover the prevalence of depression in medical students factors contributing depression.Method This a cross-sectional, questionnaire-based study.Using stratified random sampling, 237 were selected according year study.Patient Health Questionnaire (PHQ-9), based on PRIME-MD Today, used make provisional diagnosis depression. ResultsThe overall provisionally...
Purpose To investigate the risk and outcomes of second hematologic malignancies (SHMs) in a population-based cohort patients with well-differentiated thyroid cancer (WDTC) treated or not radioactive iodine (RAI). Methods Patients WDTC were identified from SEER registries. Competing regression analysis was performed to calculate risks SHMs that occurred after treatment SHM development assessed. Results Of 148,215 WDTC, 53% received surgery alone 47% RAI. In total, 783 developed an median...
We describe a series of 102 patients diagnosed from January 1, 1990 to December 31, 2015 with Type 1 monoclonal cryoglobulinemia (MoC). Symptoms were seen in 89 (87%) patients, including: cutaneous symptoms 64 (63%) purpura (n = 43, 42%) and ulcers/gangrene 35, 34%) being most common; neurological findings 33 (32%) frequently sensory neuropathy 24, 24%); vasomotor symptoms, mainly Raynaud's phenomenon 25 (25%); arthralgias 24 (24%); renal manifestations, primarily glomerulonephritis 14 (14%)...
Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines therapy. On KarMMa trial, grade ≥ 3 cytopenias and infections were common. We sought to characterize within 100 days ide-cel standard-of-care (SOC) setting. This multi-center retrospective study included 52 patients who received SOC ide-cel; 47 reached day-90 follow-up. Data censored at day 100. Grade cytopenia present among 65% 30 40% 90. Granulocyte colony...
There are limited data on patient experience after chimeric antigen receptor (CAR) T-cell therapy, especially in comparison to autologous and allogeneic transplantation, which more established forms of cellular therapy. We prospectively evaluated longitudinal patient-reported quality life (QoL), symptom burden cognition CAR-T cell therapy compared it with prospective cohorts patients undergoing stem transplantation (autoSCT) SCT (alloSCT). This was a single center study. The primary endpoint...
Chimeric antigen receptor T cell (CAR-T) therapies are Food and Drug Administration (FDA)-approved for patients with triple refractory multiple myeloma (MM). Real-world access to CAR-T therapy remains challenging owing supply chain limitations impacting manufacturing. The goal of this study was evaluate the extent issue how major centers handling challenges manufacturing slot allocation. MM physician leaders at each treatment center across United States were surveyed. We received responses...
8012 Background: Cilta-cel was FDA approved in 2022 for the treatment of RRMM. We evaluated outcomes patients treated with intended SOC cilta-cel. Methods: 12 US academic medical centers contributed data to this retrospective study. As 12/31/2022, 177 were leukapheresed and 139 received Results: The table describes study population compared CARTITUDE-1 trial. More our had extramedullary disease (EMD, 35%) high-risk cytogenetics (41%). 55% would not have met eligibility criteria CARTITUDE-1....
LBA106 Background: CARTITUDE-4 is a global, phase 3, randomized, controlled trial (NCT04181827) of ciltacabtagene autoleucel (cilta-cel), dual-binding, BCMA-targeting CAR-T cell therapy, vs standard care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, [DPd]) in lenalidomide (len)-refractory patients (pts). Methods: Eligible pts had 1–3 prior lines therapy (LOT), including PI IMiD, were len-refractory. After apheresis, randomized to cilta-cel received PVd DPd...
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted CAR T-cell therapy. Understanding the characteristics these is important patient selection development novel strategies to improve outcomes. We evaluated factors associated with progression (progression death due myeloma ≤ 3 months T infusion) in treated standard care ide-cel at...